TP53 and non-small cell lung carcinoma: Concurrently, they encapsulated the proteasome inhibitor bortezomib (BTZ) within the nanospheres, resulting in the formation of HMSNs-PEI-BTZ-p53 nanoparticles aimed at treating p53-mutated NSCLC.